Parkinsons Disease With Dementia Clinical Trial
Official title:
The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)
This is an open-label study to investigate the effects of the rivastigmine patch on attention and behavior in Parkinson's disease when associated with memory and/or thinking problems. Rivastigmine (also sold under the name Exelon) is an FDA approved medication used for the treatment of mild to moderate Alzheimer's Disease (AD) and memory or thinking problems due to Parkinson's disease. Recently a rivastigmine patch was developed, which has shown similar effectiveness with fewer side effects and increased caregiver preference when compared to capsules. This is an open-label 12 week study where 15 subjects diagnosed with Parkinson's Disease who have mild to moderate memory and/or thinking complaints will be treated with the rivastigmine patch at UCSF. This study also analyzes the mechanism by which the rivastigmine patch works in people with Parkinson's disease and memory and/or thinking problems.
Participation in this study requires four visits: a screening visit to ensure eligibility,
an initial/baseline visit where the medication is distributed at a dosage lower than the
optimal recommended dosage, a four week follow-up visit where the dosage of the medication
is increased to the optimal amount, and a final twelve week follow up visit.
- In the screening visit the patient will undergo a neurological exam (including a review
of their medical history and short physical exam), electrocardiogram ( a painless
procedure that measures electrical activity of your heart), cognitive testing (such as
memory and thinking tests), and a blood draw.
- At the Baseline/Initial visit the patient will receive a brief physical exam,
additional cognitive testing, and an MRI scan. Afterwards, the study drug will be
distributed.
- At the four week follow up visit the patient will be asked to do some abbreviated
cognitive and neurological testing and the study drug will be re-distributed at the
target dosage.
- At the final twelve week visit the patient will receive additional cognitive and
neurological testing, and an MRI scan.
- Study compliance and adverse events will be reviewed every two weeks throughout the
study, whether in person or over the phone.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Active, not recruiting |
NCT03608553 -
A Study to Evaluate Temporary Blood Brain Barrier Disruption in Patients With Parkinson's Disease Dementia
|
N/A | |
Recruiting |
NCT04148326 -
A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
|
||
Recruiting |
NCT04389437 -
OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
|
N/A | |
Completed |
NCT03774459 -
ANAVEX2-73 Study in Parkinson's Disease Dementia
|
Phase 2 | |
Active, not recruiting |
NCT02954978 -
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
|
Phase 2 |